DDInter1665 DDInter504
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Promazine {u} (Compound) resembles {v} (Compound) Desipramine
Sibutramine {u} may lead to a major life threatening interaction when taken with {v} Protriptyline
Protriptyline {u} (Compound) resembles {v} (Compound) Desipramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Atomoxetine
Atomoxetine {u} (Compound) resembles {v} (Compound) Desipramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alimemazine
Alimemazine {u} (Compound) resembles {v} (Compound) Desipramine
Sibutramine {u} may lead to a major life threatening interaction when taken with {v} Clomipramine
Clomipramine {u} (Compound) resembles {v} (Compound) Desipramine
Sibutramine {u} may lead to a major life threatening interaction when taken with {v} Amitriptyline
Amitriptyline {u} (Compound) resembles {v} (Compound) Desipramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxcarbazepine
Oxcarbazepine {u} (Compound) resembles {v} (Compound) Desipramine
Sibutramine {u} (Compound) binds {v} (Gene) SLC6A2
SLC6A2 {u} (Gene) is bound by {v} (Compound) Desipramine
Sibutramine {u} (Compound) causes {v} (Side Effect) Disturbance in sexual arousal
Disturbance in sexual arousal {u} (Side Effect) is caused by {v} (Compound) Desipramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Promazine {u} (Compound) resembles {v} (Compound) Triflupromazine
Triflupromazine {u} (Compound) resembles {v} (Compound) Desipramine
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Desipramine (Compound)
Sibutramine may lead to a major life threatening interaction when taken with Protriptyline and Protriptyline (Compound) resembles Desipramine (Compound)
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Atomoxetine and Atomoxetine (Compound) resembles Desipramine (Compound)
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Desipramine (Compound)
Sibutramine may lead to a major life threatening interaction when taken with Clomipramine and Clomipramine (Compound) resembles Desipramine (Compound)
Sibutramine may lead to a major life threatening interaction when taken with Amitriptyline and Amitriptyline (Compound) resembles Desipramine (Compound)
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Desipramine (Compound)
Sibutramine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Desipramine (Compound)
Sibutramine (Compound) causes Disturbance in sexual arousal (Side Effect) and Disturbance in sexual arousal (Side Effect) is caused by Desipramine (Compound)
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Triflupromazine (Compound) and Triflupromazine (Compound) resembles Desipramine (Compound)